Overview

Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor

Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
To determine the response rate of pazopanib when administered as monotherapy in patients with unresectable neuroendocrine tumor.
Phase:
Phase 2
Details
Lead Sponsor:
Samsung Medical Center